Single-Cell Analysis and the Endless Possibilities
ArticlesDrug Discovery and DevelopmentPodcasts

Finding New Horizons — What Possibilities Exist with Single-Cell Analysis?

Single-cell techniques offer exciting, new ways to understand personalized medicine and research. Developing these techniques at Bio-Rad is Dr. Kelly Kaihara, the third guest on Brilliant Science. Read about what makes single-cell analysis different and Kaihara’s perspective on its potential moving forward.
READ MORE →
Benefits of Flow Cytometry in Immuno-Oncology Research
ArticlesCell BiologyDrug Discovery and DevelopmentFeatured Stories

The Benefits of Flow Cytometry in Immuno-Oncology Research

Immuno-oncology, or cancer immunotherapy, research focuses heavily on the various types of cells and their behavior in cancer, so the use of flow cytometry to interrogate these cells is a no brainer. See how flow cytometry fits in this growing field of research and how it can help identify new targets and improve drug design to generate more effective and safer cancer therapeutics.
READ MORE →
Phagocytosis and Phasing Out Disease
ArticlesDrug Discovery and DevelopmentPodcasts

Phagocytosis and Phasing Out Disease

Our immune systems could soon hold the key to rewriting disease and disorder treatments. Studying the inner workings of the immune system’s primary weapon, the macrophage, with the help of CRISPR is Dr. Adam Hoppe at SDSU. Read more about his exciting work and what he hopes to accomplish next.
READ MORE →
Brilliant Science Podcast Series
ArticlesDrug Discovery and DevelopmentPodcasts

Brilliant Science Podcast Series

The Brilliant Science podcasts will introduce you to some of the amazing science being done around the world. Join us every month to see what you can learn.
READ MORE →
The Potential for CRISPR Gene Editing in HIV
ArticlesDrug Discovery and DevelopmentFeatured Stories

The Potential for CRISPR Gene Editing in HIV

The advent of CRISPR as a gene editing tool appears to have revolutionized drug discovery and development in a very short time. CRISPR-Cas9 technology is also being utilized to target HIV, to mutate or cut out the provirus. Read about what’s new in potential treatments for HIV and the challenges facing the industry.
READ MORE →
NYU Prof Harnesses CRISPR to End Muscular Dystrophy
ArticlesDrug Discovery and DevelopmentPodcasts

NYU Prof Harnesses CRISPR to End Muscular Dystrophy

On the scientific horizon are possibilities of curing genetic disorders and altering disease management — all because of CRISPR. Investigating exciting approaches to reversing the effects of muscular dystrophy with the help of CRISPR is Dr. Chengzu Long at NYU. Read more about his life, his work, and where he sees CRISPR going next.
READ MORE →
Podcast: The Ups and Downs of Biosimilar Development
ArticlesDrug Discovery and DevelopmentPodcasts

Podcast: The Ups and Downs of Biosimilar Development

In this podcast, biosimilar key opinion leader Dr. Paul Rhyne provides an overview of the current state of biosimilars and their global impact. Leveraging his 20+ years of experience in developing biologics, he discusses how cost and patient access play a big role in this new field of research.
READ MORE →
Biosimilars: Providing More Treatment Options
ArticlesDrug Discovery and DevelopmentGeneral Interest

Biosimilars: Providing More Treatment Options

It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.
READ MORE →
What's New in U.S. Biosimilar-Land?
ArticlesDrug Discovery and DevelopmentFeatured StoriesGeneral Interest

What’s New in U.S. Biosimilar-Land?

Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.
READ MORE →
Advances in Immunotherapy for Cancer
ArticlesDrug Discovery and DevelopmentGeneral Interest

Advances in Immunotherapy for Cancer

Cancer kills eight million people annually worldwide; this number will increase to 13 million by 2020. Lung, breast, colorectal, and prostate cancer are the four most commonly diagnosed cancers. Meaningful developments in immuno-oncology, or cancer immunotherapy, treatments are important now more than ever. Learn about some of the newer immunotherapies, including BiTE Antibodies and vaccines, and the companies developing them.
READ MORE →